Chapman MJ, Redfern JS, McGovern ME, Giral P. Optimizing pharmacotherapy to combat the atherogenic lipid triad. Curr Opin Cardiol 2011, DOI:10.1097/HCO.0b013e32834965e9.


A lipid triad involving an atherogenic dyslipidemia characterized by moderate/high LDL-C, low HDL-C, and elevated triglyceride (TG) occurs in numerous clinical settings associated with high cardiovascular risk. This article focuses on optimizing treatment of atherogenic dyslipidemias involving this lipid triad, emphasizing niacin-based or fibrate-based therapies.

Article link:

Curr Opin Cardiol 2011